NCT04619563View on ClinicalTrials.gov

A Trial of Anlotinib Combined With Docetaxel in EGFR Mutations Advanced Non Small Cell Lung Cancer Patients

PHASE2UnknownINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

November 4, 2020

Primary Completion Date

October 31, 2021

Study Completion Date

October 31, 2022

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

Anlotinib Hydrochloride plus Docetaxel

Anlotinib Hydrochloride (12mg, QD PO d1-14, 21days per cycle) and Docetaxel (75mg/m2 IV d1)

Trial Locations (1)

Unknown

RECRUITING

Shandong Cancer Hospital, Jinan

Sponsors
All Listed Sponsors
collaborator

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY

lead

Shandong Cancer Hospital and Institute

OTHER